Hemera enters a new phase and reorganizes governance and scientific team.

Jul 14, 2022 | Press Releases, News

The framework of roles and responsibilities expands

Each journey goes through different stages. Hemera enters a new phase, namely the development of the therapy and its evaluation in the clinical context. A transition that requires a new vision of roles and responsibilities from which comes the Board of Directors’ joint decision to redistribute tasks both in the scientific and governance areas.

Starting from the second half of 2022, Dr. Giuseppe Dastoli joins the scientific group, taking on responsibility for the Clinical Development Department, and Prof. Francesco Bifari takes over the leadership of the Therapy Development Department.

In terms of governance, the role of Chief Executive Officer is taken by Dr. Cristiana Vignoli who oversees this new phase of development of the company, while Eng. Aldo Cocchiglia continues to make his valuable contribution by focusing on company’s financing actions through existing projects and other forms of economic entrepreneurial support.

Hemera – Press contact
Lisa De Rossi
Phone: 349.7207142
Email: lisaderossinews@gmail.com